A
Ariel Hammerman
Researcher at Clalit Health Services
Publications - 73
Citations - 1019
Ariel Hammerman is an academic researcher from Clalit Health Services. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 47 publications receiving 580 citations. Previous affiliations of Ariel Hammerman include Ben-Gurion University of the Negev.
Papers
More filters
Journal ArticleDOI
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
TL;DR: Oncotype DX resulted in net QALY gain and increased overall costs, with an incremental cost-effectiveness ratio of $10,770, and represents an effective and affordable approach to favorably affect the lives of women with ESBC.
Journal ArticleDOI
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Ron Arbel,Yael Wolff Sagy,Moshe Hoshen,Erez Battat,Gil Lavie,Ruslan Sergienko,Michael Friger,Jacob G Waxman,Noa Dagan,Ran D. Balicer,Yatir Ben-Shlomo,Alon Peretz,S. Yaron,Danielle Serby,Ariel Hammerman,Doron Netzer +15 more
TL;DR: Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than amongst those who did not, and no evidence of benefit was found in younger adults.
Journal ArticleDOI
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data
Elizabeth Dudnik,Mor Moskovitz,Sameh Daher,Sivan Shamai,Ekaterina Hanovich,Ahuva Grubstein,Tzippy Shochat,Mira Wollner,Jair Bar,Ofer Merimsky,Alona Zer,Daniel A. Goldstein,Ariel Hammerman,Arnold Cyjon,Yelena Shechtman,Mahmood Abu-Amna,Dov Flex,Laila C. Roisman,Nir Peled +18 more
TL;DR: The effectiveness of nivolumab is reasonable yet less prominent than it has been demonstrated in clinical trials, and ECOG PS ≥2 is associated with poor prognosis.
Journal ArticleDOI
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years
Ron Arbel,Ruslan Sergienko,Michael Friger,Alon Peretz,Tanya Beckenstein,S. Yaron,Doron Netzer,Ariel Hammerman +7 more
TL;DR: In this paper , the authors used Cox proportional hazards regression models to estimate the association between the second booster and hospitalization and death due to COVID-19 while adjusting for demographic factors and coexisting illnesses.
Journal ArticleDOI
Systemic Therapy for Psoriasis and the Risk of Herpes Zoster: A 500,000 Person-year Study.
Guy Shalom,Devy Zisman,Haim Bitterman,Ilana Harman-Boehm,Sari Greenberg-Dotan,Jacob Dreiher,Ilan Feldhamer,Hadas Moser,Ariel Hammerman,Yoram Cohen,Arnon D. Cohen +10 more
TL;DR: Physicians may need to consider offering an HZ preventive vaccine to patients receiving combination treatment with biologic medications and methotrexate, particularly if they have additional risk factors for HZ.